Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Extrahepatic targeted delivery of oligonucleotides, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), is an attractive technology for the development of nucleic acid-based medicines. To target CD22-expressing B cells, several drug platforms have shown promise, including antibodies, antibody-drug conjugates, and nanoparticles, but to date CD22-targeted delivery of oligonucleotide therapeutics has not been reported. Here we report the uptake and enhancement of siRNA gene expression knockdown in CD22-expressing B cells using a chemically stabilized and modified CD22 glycan ligand-conjugated siRNA. This finding has the potential to broaden the use of siRNA technology, opening up novel therapeutic opportunities, and presents an innovative approach for targeted delivery of siRNAs to B cell lymphomas.


Toshimasa Harumoto, Hiroto Iwai, Mari Tanigawa, Toshiko Kubo, Toshiyuki Atsumi, Kyoko Tsutsumi, Michio Takashima, Giuseppe Destito, Rachel Soloff, Kazuma Tomizuka, Corwin Nycholat, James Paulson, Keiji Uehara. Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand-siRNA Conjugates. ACS chemical biology. 2022 Feb 18;17(2):292-298

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35020348

View Full Text